Eli Lilly and Novo Nordisk are expected to announce deals with the White House to offer the lowest dose of their weight-loss ...

The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.

Live Updates Live Coverage Updates appear automatically as they are published. Updates will appear here as they are published. Tempus AI (NASDAQ: TEM) reports third-quarter results after the close, ...

Following a lengthy R&D process, two new molecules from Biogen could add much-needed treatments for a disease that’s been difficult to pin down.

Eli Lilly and Novo Nordisk plan to announce new drug pricing deals with the White House, including for their weight loss ...

Novo Nordisk asserts its acquisition of Metsera won't pose antitrust problems as it competes with Pfizer for dominance in the ...

AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving ...

If it wasn’t already clear, Virginia is doubling down on life sciences. State officials have teamed up with a trio of top ...

London's main stock indexes dipped on Monday, dragged down by materials and utilities shares, as investors prepare for a week ...

(Reuters) -AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on ...

The blue-chip FTSE 100 inched 0.1% to 9730.1 points by 1241 GMT, building on its near 4% jump in October, while the FTSE 250 midcap index dipped 0.1% in the session. It is shaping up to be a busy ...